abstract
From PhenoPath Laboratories, PLLC, Seattle, WA, and CellNetix Pathology and Laboratories, Seattle, WA. cisacson@cellnetix.com.
OBJECTIVES:
We recently observed expression of the "lung" marker
napsin A in
ovarian clear cell carcinomas and therefore sought to determine the extent of napsin A expression in a subset of
ovarian neoplasms.
METHODS:
We identified an archival series of
ovarian
clear cell carcinomas (
n = 36), serous borderline tumors (n = 21),
high-grade serous carcinomas (n = 37), and endometrioid adenocarcinomas
(n = 29). Using standard immunohistochemical techniques on whole
sections of formalin-fixed, paraffin-embedded specimens, we employed a
panel of antibodies: napsin A (IP64), estrogen receptor (SP1), WT-1
(6F-H2), PAX-8 (BC12), and TTF-1 (SPT24).
RESULTS:
Thirty-six
of 36 clear cell carcinomas showed napsin A expression, typically in a
uniform pattern. None of the serous borderline tumors or high-grade
serous carcinomas manifested napsin A expression. Napsin A was expressed
in three (10%) of 29 endometrioid adenocarcinomas, generally in a focal
pattern.
CONCLUSIONS:
Our study showed that napsin A is an extremely sensitive (100%) marker of
ovarian
clear cell carcinomas and exhibits very high specificity (100%) in
distinguishing clear cell carcinomas from high-grade serous carcinomas
and serous borderline tumors and 90% specificity in discriminating clear
cell carcinomas from endometrioid carcinomas.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.